Study of Rapamycin Plus Ketoconazole in Advanced Cancers

Inclusion Criteria

• •Histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective.
• •Patients with hematologic malignancies (lymphoma, multiple myeloma and CLL only) are eligible to participate in the phase Ib portion of the trial only
• •At least 4 weeks since prior chemotherapy or radiation therapy (6 weeks if the last regimen included BCNU or mitomycin C).
• •Age \>18 years.
• •ECOG performance status less than or equal to 2
• •Life expectancy of more than 3 months.
• •Normal organ and marrow function as defined below:
• •* Hemoglobin ≥ 10 g/dl
• •* Leukocytes ≥ 3,000/µL
• •o WBC ≥ 1,500/µL for patients with hematologic malignancies
• •* Absolute neutrophil count ≥ 1,500/µL (≥ 1,000/µL for patients with hematologic malignancies)
• •* Absolute lymphocyte count ≥1000/µL
• •* Platelets ≥ 100,000/µL (≥ 50,000/µL for patients with hematologic malignancies)
• •* Total bilirubin within normal institutional limits
• •* AST (SGOT) and ALT (SGPT) ≤ 2.5 times institutional ULN
• •* Serum triglycerides ≤ 500 mg/dl
• •* Creatinine within normal institutional limits OR
• •* Creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.
• •Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.
• •Able to understand and the willing to sign a written informed consent document.